A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

NCT01290900 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Male Volunteers

Interventions

DRUG: NXL104
DRUG: Ceftaroline
DRUG: Placebo Infusion
DRUG: Ceftazidime
DRUG: Moxifloxacin

Sponsor

Pfizer